THANK YOU FOR SUBSCRIBING
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
“Unlike other intravaginal SUI devices on the market that are essentially mobile apps that teach women how to perform Kegel exercises, FlyteTM is a treatment with clinical outcomes backed by data, including the largest multicenter and double-blind study,” said Carrie Vollmer, VP of marketing at Pelvital. “We are excited about offering a non-surgical solution that has the potential to improve quality of life for woman at all levels of severity.” Flyte will be available through Ob-Gyns, urogynecologists, pelvic floor physical therapists and other clinicians who can diagnose, assess, and offer it as a first-line conservative treatment.![]()
Our objective is to commercialize a clinically proven, in-home SUI treatment that has the potential to improve the quality of life of millions of women who are not being treated today
Share this Article:
Tweet
|
Company
Pelvital
Headquarters
Minneapolis, MN
Management
Carrie Vollmer, V.P. of Marketing and Dale Wahlstrom, Co-Founder & CEO
Description
According to medical studies, one in every three women experiences stress urinary incontinence (SUI)—the leakage of urine due to the pressure on the bladder or urethra—at some point in their lives. Minneapolis-based pelvic health company, Pelvital, hopes to help change this. The company is working to commercialize FlyteTM, a simple in-home treatment for SUI, designed to treat weakened pelvic floor muscles and provide a good outcome at a fraction of the cost and risk of surgery. It is the only product to use mechanotherapy to treat pelvic floor muscle (PFM) disorders, the primary underlying cause of female SUI
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info